Clinical Trials Sponsored by AstraZeneca

Total 4275 results

AstraZeneca

Completed

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies | Non-Small Cell Lung Cancer (NSCLC) | Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC) | Colorectal Carcinoma (CRC)

United States
AstraZeneca

Completed

Selumetinib Paediatric NF1 Japan Study

Neurofibromatosis Type 1

Japan
AstraZeneca

Completed

A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer

Gastric Ulcer | Duodenal Ulcer | Reflux Esophagitis

Japan
AstraZeneca

Terminated

A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants

Non-alcoholic Steatohepatitis

Germany
AstraZeneca

Completed

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Asthma | Severe Eosinophilic Asthma

France, Germany, Italy, United Kingdom
AstraZeneca

Completed

Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)

Asthma

Taiwan, Korea, Republic of, Philippines, China
AstraZeneca

Terminated

Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia (GRAZE)

Hyperkalaemia

United States
AstraZeneca

Completed

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

HER2-ve Metastatic Breast Cancer | Germline BRCA1/2 Mutations | Somatic BRCA1/2 Mutations

Italy, Spain, Poland, Taiwan, Canada, France, Germany, Korea, Republic of, Hungary, Japan, Russian Federation, Turkey, United Kingdom, United States, Bulgaria
AstraZeneca

Completed

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

Healthy Volunteers

United States
AstraZeneca

Completed

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)

Advanced Solid Malignancies

United States, Germany, Italy, United Kingdom, Canada, France, Korea, Republic of, Netherlands
AstraZeneca

Active, not recruiting

Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN)

Small-Cell Lung Cancer

Poland, Korea, Republic of, United States, Spain
AstraZeneca

Completed

To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

Solid Tumours

Denmark, Belgium, United Kingdom, Netherlands
AstraZeneca

Active, not recruiting

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific (AURA17)

Non-Small Cell Lung Cancer

Korea, Republic of, China, Australia
AstraZeneca

Completed

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

Heart Failure

United States
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia. (HAYATE)

Dyslipidemia

Japan
AstraZeneca

Terminated

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

Solid Tumors

Italy, Switzerland
AstraZeneca

Completed

Capivasertib China PK Study

Advanced Solid Tumours

China
AstraZeneca

Completed

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Advanced Solid Tumours

Japan
AstraZeneca

Terminated

Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222 (COVID-19)

Coronavirus Disease 2019 (COVID-19)

Germany
AstraZeneca

Completed

Phase I Double-blind, Placebo-controlled Study of AZD7442

COVID-19

Japan
AstraZeneca

Completed

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings (DISCOVER)

Type 2 Diabetes Mellitus

Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, South Africa, Spain, Turkey, China, Netherlands, Argentina, Austria, Czechia, United Arab Emirates, Taiwan, India, Egypt, Saudi Arabia, Lebanon, Indonesia, Col... and more
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
AstraZeneca

Completed

Development of AECOPD Identification Tool (DETECT Study)

Acute Exacerbations of COPD

China
AstraZeneca

Completed

Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice (ALETHEIA)

Myocardial Infarction (MI)

Sweden, United Kingdom, United States, Italy, Germany
AstraZeneca

Completed

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Canada
AstraZeneca

Terminated

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

Acute Myeloid Leukaemia

United States, Australia
AstraZeneca

Terminated

Gefitinib Long-term Survivor Study

EGFR Mutation Positive Advanced Non-small-cell Lung Cancer

China
AstraZeneca

Completed

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria (LuCaReAl)

Oncology & Epidemiology & Lung Cancer

Algeria
AstraZeneca

Completed

ALEXANDRIA Study Egypt

Breast Cancer

Egypt
AstraZeneca

Completed

A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment

Renal Impairment | Hepatic Impairment

Bulgaria
AstraZeneca

Completed

Realize the Current Situation of COPD Patients in China (REAL)

Chronic Obstructive Pulmonary Disease COPD

China
AstraZeneca

Completed

Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting (ZENSHIN)

Prostatic Neoplasms

Japan
AstraZeneca

Completed

An INternational Frontline Ovarian Cancer Real World Management Study (INFORM)

Ovarian Neoplasms

Australia, Korea, Republic of, Taiwan
AstraZeneca

Completed

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced or

Korea, Republic of
AstraZeneca

Completed

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Advanced Malignancy

China
AstraZeneca

Completed

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Head and Neck Squamous Cell Carcinoma

Taiwan, United States, France
AstraZeneca

Terminated

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure. (SATELLITE)

Heart Failure

Denmark, Finland, Netherlands, United States, Sweden
AstraZeneca

Completed

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

Non Small Cell Lung Cancer

Korea, Republic of, Taiwan, United Kingdom, Spain, United States, Netherlands
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD)

Chronic Kidney Disease

United States, Canada, Spain, United Kingdom, Denmark, Germany, Korea, Republic of, Brazil, Hungary, Mexico, Peru, Philippines, Vietnam, China, Japan, Argentina, Ukraine, Poland, Russian Federation, India, Sweden
AstraZeneca

Completed

A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449

Asthma

New Zealand, United Kingdom
AstraZeneca

Withdrawn

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer. (LARES)

Breast Cancer

China
AstraZeneca

Completed

PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4) (HESTIA4)

Sickle Cell Disease

Belgium, United Kingdom, Italy, Spain, Kenya, Lebanon
AstraZeneca

Completed

A Study of MEDI7352 in Painful Osteoarthritis of the Knee

Chronic Pain

Germany, Sweden, United Kingdom
AstraZeneca

Completed

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)

Asthma

United States, Canada, France, Germany, Spain, United Kingdom, Poland, Turkey, Argentina, Australia, Ukraine, Czechia, Russian Federation, Bulgaria, Chile
AstraZeneca

Completed

Long-Term Follow-Up and Management Patterns of Patients With Acute Coronary Syndrome in Middle East and Africa (TOURACO)

Acute Coronary Syndrom

Qatar
AstraZeneca

Completed

SABINA INTERNATIONAL

Asthma

Argentina
AstraZeneca

Completed

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM)

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Australia
AstraZeneca

Completed

Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT) (REFLECT)

Lung Cancer

Bulgaria

3

Subscribe